Kazia Therapeutics Advances Cancer Research Amid Nasdaq Compliance Challenge

The latest update is out from Kazia Therapeutics ( (KZIA) ).

On May 15, 2025, Kazia Therapeutics announced significant progress in its research and development efforts, including a research grant from The Michael J. Fox Foundation to explore paxalisib for Parkinson’s disease and the launch of a clinical trial combining paxalisib with immunotherapy for advanced breast cancer. The company also aligned with the FDA on a phase 3 study design for paxalisib in glioblastoma treatment. Despite these advancements, Kazia received a notification from Nasdaq regarding its market value, prompting the company to explore strategies to regain compliance.

The most recent analyst rating on (KZIA) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Kazia Therapeutics stock, see the KZIA Stock Forecast page.

Spark’s Take on KZIA Stock

According to Spark, TipRanks’ AI Analyst, KZIA is a Underperform.

Kazia Therapeutics has a low overall stock score due to significant financial instability marked by declining revenues, negative equity, and cash flow issues. Technical indicators suggest bearish momentum, and poor valuation metrics reflect the company’s unprofitability. The absence of dividends and positive earnings call or corporate events data further emphasize the company’s challenges.

To see Spark’s full report on KZIA stock, click here.

More about Kazia Therapeutics

Kazia Therapeutics Limited is an oncology-focused drug development company based in Sydney, Australia. The company specializes in developing innovative cancer therapies, with a particular focus on its lead drug candidate, paxalisib, which is being explored for various cancer treatments including glioblastoma and breast cancer.

Average Trading Volume: 43,801

Technical Sentiment Signal: Sell

Current Market Cap: $4.02M

See more data about KZIA stock on TipRanks’ Stock Analysis page.